AzTrials
AzTrials

Inflammation BiomarkersNCT06618716

Individual Differences in Acute Response to Experimental Inflammation: Microcirculatory Changes and Psychological Predictors

A study testing endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS) and Placcebo in people with Inflammation Biomarkers and Inflammation, run by University Hospital, Linkoeping at 1 site in Sweden.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The physiological and behavioral responses to inflammatory vary greatly between individuals. The knowlegde about what causes these differences is sparse but plausible explanations are variations in sensitivity to peripheral inflammation. Read more about this study

Who is it for?
Ages 18 to 40 yearsHealthy volunteers can take part
Conditions the study is for
Inflammation Biomarkers, Inflammation
What is being tested?
endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS) and Placcebo
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
25 participants
Where
1 siteSweden
Study dates
17 Sep 2024to 11 Mar 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 40 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Healthy
  • 18-40 years-old
  • Consent form signed
  • Having a Swedish personal identification number (personnummer)

Who cannot join

  • Non-fluent in Swedish
  • Unable to read
  • Unable or unwilling to provide informed consent
  • BMI below 18.5 or above 25 kg/m2
  • Smoking
  • Excessive alcohol consumption
Show all 23Show fewer
  • Pregnancy or breastfeeding
  • Positive on drug screening
  • Current somatic disease including skin disease affecting the measurement areas
  • Current depression, anxiety, sleep disturbances or other psychiatric illnesses
  • Abnormal blood analyses: abnormal clinical levels in blood cell counts, hemoglobin, sodium, potassium, chloride, calcium, phosphate, creatinine, blood urea nitrogen, uric acid, glucose, aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transpeptidase, bilirubin, thromboplastin time and partial thromboplastin time
  • High-sensitivity C-reactive protein \> 10 mg/L.
  • History of cardiovascular, pneumological, immune disease
  • Moderate viral or bacterial infection in the past two weeks
  • Severe and/or long-term COVID-19: positive SARS-CoV-2 PCR-test or antigen-test and/or history of symptoms since February 2020 indicative of infection with SARS-CoV-2 (fever, cough, sore throat, runny or blocked nose, nausea, muscle pain, shortness of breath), which was of high intensity and/or of long duration (≥ 8 weeks).
  • Recent vaccination (within previous two weeks)
  • Abnormal cardiovascular measurements
  • Current or previous cancer
  • Any concomitant medication other than contraceptives (14 days prior to the start and throughout the study period)
  • Shift work or irregular sleep-wake cycle (within 14 days of the study period)
  • Needle anxiety or blood phobia
  • Invisible veins in the antecubital area of the arms or very difficult blood sampling (self-reported or experienced during screening).
  • Previous participation in a study involving administration of LPS

Trial locations and contacts

1 site in 1 country.

Sweden1 site
  • Department of emergency medicine, Linköping University Hospital, Region Östergötland

    Linköping

Other trials in Sweden

About this study

Official title: Individual Differences in the Acute Response to Experimentally Induced Inflammation: Microcirculatory Changes and Psychological Predictors

The physiological and behavioral responses to inflammatory vary greatly between individuals. The knowlegde about what causes these differences is sparse but plausible explanations are variations in sensitivity to peripheral inflammation. The goal of the study is to understand microcirculatory changes in skin and their possible correlation with conventional measurements of sickness and disease in humans. A better understanding of possible psychological predictors of sickness behaviour is also warranted as it may affect the results.

The general aim of the study is to assess microcirculatory changes in skin of the face, chest, hands and feet using different optical imaging techniques, and to identify psychological predictors in the acute behavioral response to experimentally induced inflammation. The participants are healthy volunteers in the age of 18-40 years of both sex/genders. The main questions to answer are:

Read more
  1. How do acute inflammation change microcirculation in the skin as measured by temperature, red blood cell concentration, blood flow and spectral changes correlated with fluids and other proteins.
  2. Can a stronger behavioral response to experimental endotoxemia be predicted by psychological factors of the individuals?

It is a blinded with-in subject, crossover design where the participants will receive placebo-injection with saline on one study day and LPS-injection the other study day in a randomized order.

Participants will on the study days

  • Fill in psychometric questionnaires
  • Be measured with bio-optical imaging methods at regular intervalls.
  • Be monitored with regular medical parameters such as blood pressure, oxygen saturation, puls etc When the volunteers feel recovered and the medical staff are confident of the recovery the volunteers will be discharged.
Read the detailed description

Background Acute illness manifest itself not only by physiological responses such as e.g. fever, pain and nausea, but is often accompanied by psychological and behavioral changes such as sleep/wake disturbances, fatigue, loss of appetite and depression. The physiological and behavioral responses to inflammatory activation vary greatly between individuals. The knowledge about what causes these differences is sparse, but plausible explanations are variations in sensitivity to peripheral inflammation and inflammation-induced brain changes. As the skin is readily accessible, it provides an appropriate site to assess microvascular reactivity during inflammation. Moreover, recent technological advances have provided simple and non-invasive methods to assess skin microvascular function. Therefore, human cutaneous circulation could be used as a surrogate marker of systemic microvascular function in inflammation. In the present study, we use experimentally induced immunological activation in healthy humans to study microcirculatory skin changes as well as behavioral predictors of individual sensitivity to an acute inflammatory stimulus.

The model of experimental endotoxemia to induce acute inflammation The model of experimental endotoxemia is a well-accepted and frequently used model to study the neuropsychiatric effects of pro-inflammatory cytokines, both in animals and in humans. The model is based on the sterile activation of the immune system, obtained by intravenous injection of an endotoxin, lipopolysaccharide (LPS), a wall component of gram-negative bacteria such as E. coli. Injection of LPS will affect the functionality of the vascular endothelium. Positioned at the interface between circulating blood and surrounding tissue, endothelial cells, which line the inner walls of blood vessels, play a crucial role in the response to pathogens. The endothelium serves various functions essential for maintaining organ homeostasis, including vasoregulation, selective vascular permeability, and providing an anticoagulant surface. However, during infection, the normal physiological functions of the endothelium are disrupted, contributing to the organ failure characteristic of sepsis. Importantly, the response to inflammation during experimental endotoxemia differs substantially across individuals. This holds for the degree of increase in inflammatory cytokines, the neural response, as well as the behavioral changes that entail inflammation. It should be noted that the neuropsychiatric response to inflammation is not explained fully by the magnitude of the inflammatory response, indicating that other factors are involved. Recent research points toward the importance of top-down mechanisms in modifying the effect of inflammation on behavior. Such mechanisms might include pre-existent emotional status and beliefs about the intensity of which one will become sick after an infection. Identifying the predictors of a heightened behavioral response to inflammation would help identifying markers of inflammation-associated neuropsychiatric vulnerability, but this has rarely been investigated.

General aim The general aim of the study is to assess microcirculatory changes in skin of the face, chest, hands and feet using different optical imaging techniques, and to identify psychological predictors in the acute behavioral response to experimentally induced inflammation.

Primary research questions

The main research questions are:

  1. to assess how acute inflammation affects:
  • the microcirculation in skin such as face, chest, arms, hands and feet as investigated with different non-invasive optical imaging techniques:
  • Core temperature changes
  • Facial temperature changes
  • Changes in equivalents to red blood cell concentration and blood flow
  • Spectral changes in skin possibly correlated with fluids and other proteins affected by microcirculatory changes
  1. to assess whether a stronger behavioral response (i.e. sickness behavior, negative mood, fatigue, anxiety, pain) to experimental endotoxemia is predicted by:
  • higher interoceptive sensitivity as measured by self-report and an objective task (heartrate discrimination task);
  • less cognitive resilience (i.e. self-efficacy, optimism, perseverance, coping strategies, ability to update beliefs in the fact of contradictory evidence);
  • worse baseline emotional status (i.e. trait anxiety, fatigue, perceived stress);
  • stronger health anxiety and disgust tendencies;
  • Sociocultural factors that have been found to relate to sickness behavior, such as stoic endurance of pain and discomfort, familism, individualism, and collectivism;
  • baseline biological motion pattern (walking speed, rigidity of gait, and slumped posture);

Methods Research principals The research principals are Region Östergötland, Karolinska Institutet and Stockholm University, Sweden. Data collection will be conducted at the Emergency Medicine Research Center (EMRC). Processing of data will be conducted at EMRC, Region Östergötland, Karolinska Institutet and Stockholm University.

Study design The study will be conducted at the Emergency Medicine Research Center at the University Hospital of Linköping. The study will follow a double-blind within-subject crossover placebo-controlled design. All subjects will receive an intravenous administration of LPS at a dose of up to 0.8 ng/kg body weight once, and an intravenous administration of placebo once, in a randomized order and with at least 4 weeks of wash-out period. Upon arrival, volunteers will be placed on a hospital bed in a single room and a catheter will be placed in the forearm or hand to avoid multiple needle insertion. A urine sample for pregnancy testing and drug screening will be obtained for safety reasons. The participants will then complete the baseline questionnaires, and the baseline blood sample will be drawn. After the baseline assessments, volunteers will receive the LPS or placebo injection. Vital signs (pulse, blood pressure, blood-oxygen saturation, respiratory frequency) will be continuously monitored and recorded at 30-minute intervals. Body temperature will be monitored and recorded every 30 minutes with regular tympanic thermometer, as well as continuously, using bio-optical imaging techniques. Blood samples will be taken approximately every hour to measure the inflammatory response (see "assessments - inflammatory markers from blood samples" below). Bio-optical imaging will be performed once before injection and at several occasions after the injection. Web-based questionnaires will be completed regularly to measure the sickness and emotional response will be completed by the participants just after acquisition of blood samples. Several behavioral tasks will be conducted during the study day. Volunteers will be discharged 6-10 hrs or when considered recovered by medical staff, after the injection, following a medical examination.

Being tested
endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS), Placcebo
Keywords
Microcirculatory status, Sickness behaviour, Lipopolysaccharide, Non-invasive monitoring
Medical subject headings
Inflammation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS)Biological

    Intravenous administration of endotoxin (0.8 ng/kg body weight)

  • PlacceboOther

    Placebo injection of 0.9% NaCl

Study groups in NCT06618716
Study groupRoleWhat they receive
EndotoxinActive comparatorThe USP (United States Pharmacopeia Convention) Endotoxin RS (LPS; Endotoxin Reference Standard, Escherichia coli, Pharmacopeia, Rockville, MD, US) will be ordered.and comes as a lyophilized (freeze-dried) powder, and each vial contains 10,000 USP Endotoxin Units. Each vial contains approximately 1 microgram of Endotoxin. The lyophilized LPS will be dissolved in 5mL sterile water to obtain a solution at 200 ng/mL. This solution will be aliquoted in 400μL (thus containing 80ng endotoxin) and stored at -20°C. Aliquots will be sent for microbial safety testing routine and verification of endotoxin concentration to a certified laboratory. On the study day, 2100μL of physiological saline (sterile, pyrogen-free isotonic NaCl solution) will be added to the aliquot to obtain a final concentration of 32 ng/mL. The amount of solution to inject will then be calculated according to the participant's weight [in mL = (0.8 x weight) / 32].
Receives: Biological: endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS)
PlaceboPlacebo comparatorAn equivolume of sterile physiological saline (NaCl 0.9%) will be used as placebo.
Receives: Other: Placcebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. How does inflammation affect the behavioral response?

    Behavioral response in psychometric tests measuring sickness behavior, negative mood, anxiety and fatigue on Likert scales.

    Measured: Baseline

  2. How does inflammation affect the behavioral response?

    Behavioral response in psychometric tests measuring sickness behavior, negative mood, anxiety and fatigue on Likert scales.

    Measured: during the intervention

  3. How does inflammation affect the behavioral response?

    Behavioral response in psychometric tests measuring sickness behavior, negative mood, anxiety and fatigue on Likert scales.

    Measured: after the intervention

  4. Microcirculatory changes in skin measured with bio-optical instruments

    • Red Blood Cell tissue fraction - %

    Measured: Baseline

  5. Microcirculatory changes in skin measured with bio-optical instruments

    • Red Blood Cell tissue fraction - %

    Measured: during the intervention

  6. Microcirculatory changes in skin measured with bio-optical instruments

    • Red Blood Cell tissue fraction - %

    Measured: after the intervention

  7. Microcirculatory changes in skin measured with bio-optical instruments

    • Blood flow - mm/s

    Measured: Baseline

  8. Microcirculatory changes in skin measured with bio-optical instruments

    Blood flow - mm/s

    Measured: during the intervention

  9. Microcirculatory changes in skin measured with bio-optical instruments

    • Blood flow - mm/s

    Measured: after the intervention

  10. Changes in skin and core temperature

    Measured in degrees Celsius

    Measured: Baseline

  11. Changes in skin and core temperature

    Measured in degrees Celsius

    Measured: during the intervention

  12. Changes in skin and core temperature

    Measured in degrees Celsius

    Measured: after the intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Oct 2024
  2. Study start17 Sep 2024
  3. Primary completion11 Mar 2025
  4. Study completion11 Mar 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Crossover
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
25 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06618716
Sponsor's protocol ID
2023-07974-01
Other IDs
2023
Status last verified
May 2026
First submitted
12 Sep 2024
Last updated
8 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Pseudomized data on the psychometric tests and kinetic tests will be shared with other researchers.

Publications

  • Gustavsson H, Toll R, Fahlander S, Meyer F, Olwegard B, Hultman M, Lasselin J, Henricson J, Wilhelms D. Physiological limits of capillary refill time: a human endotoxemia study. Crit Care. 2026 Aug 31;30(1):461. doi: 10.1186/s13054-026-06247-8.

    PubMed 42706575

Questions about this trial

What is this clinical trial studying?

A study testing endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS) and Placcebo in people with Inflammation Biomarkers and Inflammation, run by University Hospital, Linkoeping at 1 site in Sweden.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

How does inflammation affect the behavioral response? (time frame: Baseline). The study lists 12 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06618716, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2026; AzTrials last refreshed its copy on 30 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in